PortalPublikationenTreatment of anemia with darbepoetin alfa in systolic heart ...

Treatment of anemia with darbepoetin alfa in systolic heart failure

Standard

Treatment of anemia with darbepoetin alfa in systolic heart failure. / Swedberg, Karl; Young, James B; Anand, Inder S; Cheng, Sunfa; Desai, Akshay S; Diaz, Rafael; Maggioni, Aldo P; McMurray, John J V; O'Connor, Christopher; Pfeffer, Marc A; Solomon, Scott D; Sun, Yan; Tendera, Michal; van Veldhuisen, Dirk J; RED-HF Committees.

in: NEW ENGL J MED, Jahrgang 368, Nr. 13, 28.03.2013, S. 1210-1219.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Swedberg, K, Young, JB, Anand, IS, Cheng, S, Desai, AS, Diaz, R, Maggioni, AP, McMurray, JJV, O'Connor, C, Pfeffer, MA, Solomon, SD, Sun, Y, Tendera, M, van Veldhuisen, DJ & RED-HF Committees 2013, 'Treatment of anemia with darbepoetin alfa in systolic heart failure', NEW ENGL J MED, Jg. 368, Nr. 13, S. 1210-1219. https://doi.org/10.1056/NEJMoa1214865

APA

Swedberg, K., Young, J. B., Anand, I. S., Cheng, S., Desai, A. S., Diaz, R., Maggioni, A. P., McMurray, J. J. V., O'Connor, C., Pfeffer, M. A., Solomon, S. D., Sun, Y., Tendera, M., van Veldhuisen, D. J., & RED-HF Committees (2013). Treatment of anemia with darbepoetin alfa in systolic heart failure. NEW ENGL J MED, 368(13), 1210-1219. https://doi.org/10.1056/NEJMoa1214865

Vancouver

Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. NEW ENGL J MED. 2013 Mär 28;368(13):1210-1219. https://doi.org/10.1056/NEJMoa1214865

Bibtex

@article{1c28f371e4d146f4b47489051d36ee65,
title = "Treatment of anemia with darbepoetin alfa in systolic heart failure",
abstract = "BACKGROUND: Patients with systolic heart failure and anemia have worse symptoms, functional capacity, and outcomes than those without anemia. We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic heart failure and anemia.METHODS: In this randomized, double-blind trial, we assigned 2278 patients with systolic heart failure and mild-to-moderate anemia (hemoglobin level, 9.0 to 12.0 g per deciliter) to receive either darbepoetin alfa (to achieve a hemoglobin target of 13 g per deciliter) or placebo. The primary outcome was a composite of death from any cause or hospitalization for worsening heart failure.RESULTS: The primary outcome occurred in 576 of 1136 patients (50.7%) in the darbepoetin alfa group and 565 of 1142 patients (49.5%) in the placebo group (hazard ratio in the darbepoetin alfa group, 1.01; 95% confidence interval, 0.90 to 1.13; P=0.87). There was no significant between-group difference in any of the secondary outcomes. The neutral effect of darbepoetin alfa was consistent across all prespecified subgroups. Fatal or nonfatal stroke occurred in 42 patients (3.7%) in the darbepoetin alfa group and 31 patients (2.7%) in the placebo group (P=0.23). Thromboembolic adverse events were reported in 153 patients (13.5%) in the darbepoetin alfa group and 114 patients (10.0%) in the placebo group (P=0.01). Cancer-related adverse events were similar in the two study groups.CONCLUSIONS: Treatment with darbepoetin alfa did not improve clinical outcomes in patients with systolic heart failure and mild-to-moderate anemia. Our findings do not support the use of darbepoetin alfa in these patients. (Funded by Amgen; RED-HF ClinicalTrials.gov number, NCT00358215.).",
keywords = "Aged, Anemia/drug therapy, Darbepoetin alfa, Double-Blind Method, Erythropoietin/adverse effects, Female, Heart Failure, Systolic/complications, Hematinics/adverse effects, Hemoglobins/analysis, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Shock, Septic/etiology, Stroke/etiology, Thromboembolism/etiology, Treatment Failure",
author = "Karl Swedberg and Young, {James B} and Anand, {Inder S} and Sunfa Cheng and Desai, {Akshay S} and Rafael Diaz and Maggioni, {Aldo P} and McMurray, {John J V} and Christopher O'Connor and Pfeffer, {Marc A} and Solomon, {Scott D} and Yan Sun and Michal Tendera and {van Veldhuisen}, {Dirk J} and {RED-HF Committees} and Kai M{\"u}llerleile",
year = "2013",
month = mar,
day = "28",
doi = "10.1056/NEJMoa1214865",
language = "English",
volume = "368",
pages = "1210--1219",
journal = "NEW ENGL J MED",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "13",

}

RIS

TY - JOUR

T1 - Treatment of anemia with darbepoetin alfa in systolic heart failure

AU - Swedberg, Karl

AU - Young, James B

AU - Anand, Inder S

AU - Cheng, Sunfa

AU - Desai, Akshay S

AU - Diaz, Rafael

AU - Maggioni, Aldo P

AU - McMurray, John J V

AU - O'Connor, Christopher

AU - Pfeffer, Marc A

AU - Solomon, Scott D

AU - Sun, Yan

AU - Tendera, Michal

AU - van Veldhuisen, Dirk J

AU - RED-HF Committees

AU - Müllerleile, Kai

PY - 2013/3/28

Y1 - 2013/3/28

N2 - BACKGROUND: Patients with systolic heart failure and anemia have worse symptoms, functional capacity, and outcomes than those without anemia. We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic heart failure and anemia.METHODS: In this randomized, double-blind trial, we assigned 2278 patients with systolic heart failure and mild-to-moderate anemia (hemoglobin level, 9.0 to 12.0 g per deciliter) to receive either darbepoetin alfa (to achieve a hemoglobin target of 13 g per deciliter) or placebo. The primary outcome was a composite of death from any cause or hospitalization for worsening heart failure.RESULTS: The primary outcome occurred in 576 of 1136 patients (50.7%) in the darbepoetin alfa group and 565 of 1142 patients (49.5%) in the placebo group (hazard ratio in the darbepoetin alfa group, 1.01; 95% confidence interval, 0.90 to 1.13; P=0.87). There was no significant between-group difference in any of the secondary outcomes. The neutral effect of darbepoetin alfa was consistent across all prespecified subgroups. Fatal or nonfatal stroke occurred in 42 patients (3.7%) in the darbepoetin alfa group and 31 patients (2.7%) in the placebo group (P=0.23). Thromboembolic adverse events were reported in 153 patients (13.5%) in the darbepoetin alfa group and 114 patients (10.0%) in the placebo group (P=0.01). Cancer-related adverse events were similar in the two study groups.CONCLUSIONS: Treatment with darbepoetin alfa did not improve clinical outcomes in patients with systolic heart failure and mild-to-moderate anemia. Our findings do not support the use of darbepoetin alfa in these patients. (Funded by Amgen; RED-HF ClinicalTrials.gov number, NCT00358215.).

AB - BACKGROUND: Patients with systolic heart failure and anemia have worse symptoms, functional capacity, and outcomes than those without anemia. We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic heart failure and anemia.METHODS: In this randomized, double-blind trial, we assigned 2278 patients with systolic heart failure and mild-to-moderate anemia (hemoglobin level, 9.0 to 12.0 g per deciliter) to receive either darbepoetin alfa (to achieve a hemoglobin target of 13 g per deciliter) or placebo. The primary outcome was a composite of death from any cause or hospitalization for worsening heart failure.RESULTS: The primary outcome occurred in 576 of 1136 patients (50.7%) in the darbepoetin alfa group and 565 of 1142 patients (49.5%) in the placebo group (hazard ratio in the darbepoetin alfa group, 1.01; 95% confidence interval, 0.90 to 1.13; P=0.87). There was no significant between-group difference in any of the secondary outcomes. The neutral effect of darbepoetin alfa was consistent across all prespecified subgroups. Fatal or nonfatal stroke occurred in 42 patients (3.7%) in the darbepoetin alfa group and 31 patients (2.7%) in the placebo group (P=0.23). Thromboembolic adverse events were reported in 153 patients (13.5%) in the darbepoetin alfa group and 114 patients (10.0%) in the placebo group (P=0.01). Cancer-related adverse events were similar in the two study groups.CONCLUSIONS: Treatment with darbepoetin alfa did not improve clinical outcomes in patients with systolic heart failure and mild-to-moderate anemia. Our findings do not support the use of darbepoetin alfa in these patients. (Funded by Amgen; RED-HF ClinicalTrials.gov number, NCT00358215.).

KW - Aged

KW - Anemia/drug therapy

KW - Darbepoetin alfa

KW - Double-Blind Method

KW - Erythropoietin/adverse effects

KW - Female

KW - Heart Failure, Systolic/complications

KW - Hematinics/adverse effects

KW - Hemoglobins/analysis

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Proportional Hazards Models

KW - Shock, Septic/etiology

KW - Stroke/etiology

KW - Thromboembolism/etiology

KW - Treatment Failure

U2 - 10.1056/NEJMoa1214865

DO - 10.1056/NEJMoa1214865

M3 - SCORING: Journal article

C2 - 23473338

VL - 368

SP - 1210

EP - 1219

JO - NEW ENGL J MED

JF - NEW ENGL J MED

SN - 0028-4793

IS - 13

ER -